Granted Patent
B2
US 8,242,080 · App. 12/444,914 · Granted Aug 14, 2012
Inhibitors of the EGFR kinase targeting the asymmetric activating dimer interface
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides methods and compositions for the modulation of EGFR activity. In particular, inhibition of EGFR activation through an allosteric mechanism is discloses, as is a method for targeted drug discovery and design based on models of the three dimensional structure of the kinase domains of the protein dimers.
Claims (2)
1. An isolated polypeptide which is at least about 95% homologous to a sequence which is selected from SEQ ID NOs: 1-5.
2. A pharmaceutical composition comprising one or more isolated polypeptides with amino acid sequence selected from SEQ ID NOs: 1-5, wherein said one or more polypeptides are combined with at least one pharmaceutically acceptable carrier.
Assignments (2)
CONFIRMATORY LICENSE
Recorded Jun 2, 2010
From: UNIVERSITY OF CALIFORNIA BERKELEY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024467/0976 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 30, 2009
From: KURIYAN, JOHN; ZHANG, XUEWU; COLE, PHILIP
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 023581/0907 →
Continuity (3)
Provisional Application
60851668
· Oct 13, 2006
Provisional Application
60851921
· Oct 13, 2006